Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for FBRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 198.46M
March 31, 2026 58.22M
December 31, 2025 76.96M
September 30, 2025 93.41M
June 30, 2025 106.14M
March 31, 2025 45.86M
December 31, 2024 58.36M
September 30, 2024 16.36M
June 30, 2024 24.50M
March 31, 2024 30.44M
December 31, 2023 37.12M
September 30, 2023 46.18M
June 30, 2023 30.42M
March 31, 2023 35.90M
December 31, 2022 41.10M
September 30, 2022 44.05M
June 30, 2022 38.55M
March 31, 2022 40.04M
December 31, 2021 42.04M
September 30, 2021 45.66M
June 30, 2021 50.80M
Date Value
March 31, 2021 54.76M
December 31, 2020 58.76M
September 30, 2020 20.18M
June 30, 2020 27.75M
March 31, 2020 14.23M
December 31, 2019 6.939M
September 30, 2019 55.34M
June 30, 2019 68.32M
March 31, 2019 80.12M
December 31, 2018 96.09M
September 30, 2018 79.85M
June 30, 2018 79.46M
March 31, 2018 74.00M
December 31, 2017 88.72M
September 30, 2017 99.57M
June 30, 2017 108.64M
March 31, 2017 28.88M
December 31, 2016
September 30, 2016
June 30, 2016
March 31, 2016 52.56M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
argenx SE --
ACADIA Pharmaceuticals, Inc. 956.47M
Alnylam Pharmaceuticals, Inc. 3.308B
Anika Therapeutics, Inc. 38.41M
Savara, Inc. 173.03M